Allogene Therapeutics
Zachary (Zach) J. Roberts, MD, Ph.D., is the Executive Vice President of Research and Development at Allogene. Zach is a trained immunologist and board-certified oncologist with extensive experience in clinical oncology, including the development of cell therapies. Before joining Allogene, Zach was Chief Medical Officer of Instil Bio, where he led the development of both clinical and pre-clinical programs. Prior to that, Dr. Roberts held various roles of increasing responsibility at Kite Pharma (acquired by Gilead in 2017), where he was instrumental in the development and execution of the ZUMA trials across multiple indications for Yescarta®, the first autologous CAR T therapy approved for non-Hodgkin lymphoma. Before joining Kite, Zach led several solid tumor studies at Amgen. He holds an MD and Ph.D. in immunology from the University of Maryland, Baltimore, and completed clinical and post-graduate training at Massachusetts General Hospital and the Dana-Farber Cancer Institute.
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.